Latest Headlines

Latest Headlines

Let's make a med tech deal: J&J, Medtronic, Apple, Google sit on piles of cash

Med tech is attracting a huge range of strategic investors right now. Healthcare is almost universally recognized as in need of rationalization--the application of technology in the effort to achieve better outcomes at lower costs. Medical devices and diagnostics, and the data that they generate, are expected to be central to achieving that goal in the coming decades.

Can Abbott afford St. Jude and Alere? Moody's doubts it

Abbott Laboratories is seeking a new path to growth--and it's betting big that med tech is it. The company is taking on two of the largest M&A transactions in history at the same time: the more than $5.8 billion purchase of diagnostics player Alere that it announced at the start of February and the more than $25 billion buy of cardiovascular device player St. Jude Medical that was disclosed in late April.

Alere rejects Abbott's $50M breakup offer for megamerger deal

Abbott has avoided addressing rumors that its deal with point-of-care diagnostics maker Alere is on the rocks. But according to Alere, the Illinois med tech wants out.

Abbott changes its tune, snatches up St. Jude in $25B deal

Abbott said last year that it wasn't interested in St. Jude, but now, the company is changing its tune. The Illinois devicemaker will shell out $25 billion for St. Jude to gain ground in the cardiovascular and neuromodulation markets.

Jury clears Abbott in $1B+ false claims trial over off-label uses of bile duct stents

Abbott Laboratories was cleared by a Texas federal jury of accusations it violated the False Claims Act by wrongly marketing bile duct stents in a whistleblower case that sought more than $1 billion in damages.

Abbott Absorb bioresorbable stent earns unanimous recommendation from FDA panel

Abbott's Absorb bioresorbable stent took a step closer to FDA approval, winning the overwhelming backing of an FDA advisory panel of experts, who voted 9-0 (with one abstention) to recommend approval of the device based on an analysis of its risks and rewards.

FDA panelists to focus on use of Abbott's Absorb in small vessels during deliberations

Questionable data among patients with small vessels is the dominant issue at hand during the FDA panel's consideration of Abbott's Absorb bioresorbable scaffold.

DOJ targets Alere over international sales for point-of-care tests

Diagnostics maker Alere seemed to have closed one chapter after agreeing to sell out to Abbott last month. But some of the company's problems are coming back to haunt it as the U.S. Department of Justice (DOJ) investigates Alere's international sales practices.

UPDATED: Pfizer, Abbott cough syrups banned by Indian regulator in fight over opiates

Pfizer and Abbott cut production on their popular cough medicines in India last year after officials imposed new regs to fight the smuggling of opiates into Bangladesh. Now regulators have banned the products altogether, leaving Pfizer to scramble to court Monday for an order staying the action as it tries to sort out the matter.

FDA panel set to review its first bioresorbable stent, Abbott's Absorb

One of the most anticipated FDA panel meetings in years will commence in Gaithersburg, MD, on March 15, that of Abbott's Absorb BVS bioresorbable stent. The stent is a paradigm-shifting device, and the data show noninferiority to Abbott's current standard-of-care Xience drug-eluting stent.